Valion Bio, Inc.

Valion Bio, Inc.

TIVC · Nasdaq

Valion Bio, Inc. (TIVC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Valion Bio, Inc. in 2026.

Earnings calendar

Next earnings date

—

Not scheduled

EPS estimate

—

Revenue estimate

—

Past earnings

18 May 2026
EPS actual
—
estimate -85.00
Revenue actual
—
estimate 1.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
20 Mar 2025
EPS actual
—
estimate -85.00
Revenue actual
—
estimate 1.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Michael R. Cavanaugh
Employees
52
IPO date
11 Nov 2021
ISIN
US8887053085
Website
valionbio.com

Frequently asked questions

What was Valion Bio, Inc.'s most recent earnings date?

Valion Bio, Inc. (TIVC) last reported earnings on May 18, 2026.

Where is Valion Bio, Inc. stock listed?

Valion Bio, Inc. (TIVC) is listed on Nasdaq.